the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

154

TOD 10/

Our authors are among the

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Structural Relationship Study of Octanol-Water Partitioning Coefficients and Total Biodegradation of Barbiturate Medicines by Randić Descriptor

Avat (Arman) Taherpour¹*, Zhiva Taherpour² and Omid Taherpour³
¹Chemistry Department, Graduate School, Islamic Azad University, Arak Branch,
²Cardiology Department, Golestan Hospital, Ahwaz,
³Dentistry Faculty, Centro Escolar University,
¹¹²Iran
³Philippines

1. Introduction

Insomnia is most often defined by an individual's report of sleeping difficulties.[1] One definition of insomnia is difficulties in initiating and maintaining sleep, or non-restorative sleep, associated with impairments of daytime functioning or marked distress for more than 1 month."[1,2] insomnia is most often thought of as both a sign[1,3] and a symptom[1,4] that can accompany several sleep, medical, and psychiatric disorders, characterized by persistent difficulty falling asleep and staying asleep or sleep with bad quality. Specialists in sleep medicine have been attempted to diagnose many different sleep disorders. Patients with various disorders including delayed sleep phase syndrome are often misdiagnosed as primary insomnia. When a person has trouble for getting to sleep but has a normal sleep pattern once asleep, circadian rhythm disorder has almost the same cause. In many cases, insomnia is co-morbid with another disease, side-effects of medications, or a psychological problem. Approximately half of all causes of insomnia are related to psychiatric disorders.[1-4] It is possible that insomnia represents a significant risk for the development of a subsequent psychiatric disorder."[1] Sleep-onset insomnia is difficulty falling asleep at the beginning of the night, often a symptom of anxiety disorders or the delayed sleep phase disorder.


There are two types of insomnia: primary insomnia and secondary insomnia. Primary insomnia means that a person having sleep problems that are not directly associated with any other health condition or problem. Secondary insomnia means that a person having sleep problems because of something else, such as a health condition (like asthma, depression, arthritis, cancer, or heartburn); pain; medication they are taking; or a substance they are using (like alcohol and other compounds).[5-9]

^{*} Corresponding Author

Pharmacological treatments have been used mainly to reduce symptoms in acute insomnia; their role in the management of chronic insomnia remains unclear.[1-4]It is important to identify or rule out medical and psychological causes before deciding on the treatment for insomnia.[1,10] Attention to sleep hygiene is an important first line treatment strategy and should be tried before any pharmacological approach is considered.[1,11]

2. Barbiturates

Barbiturates are drugs that act as central nervous system depressants. By virtue of this, they produce a wide spectrum of effects, from mild sedation to total anesthesia. Barbiturates are also effective as anxiolytics, hypnotics, and anticonvulsants.[12] Barbiturates are still widely used in surgical anesthesia, especially to induce anesthesia. These compounds are derivatives of barbituric acid. Barbituric acid was first synthesized in 1864, by Adolf von Baeyer. The synthesis was done by condensing urea (an animal waste product) with diethyl malonate. [12,13] Barbiturates were first introduced for medical use in the early 1900s. More than 2,500 barbiturates have been synthesized, and at the height of their popularity, about 50 were marketed for human use. Barbiturates produce a wide spectrum of central nervous system depression, from mild sedation to coma, and have been used as sedatives, hypnotics, anesthetics, and anticonvulsants. The primary differences among many of these products are how fast they produce an effect and how long those effects last. Barbiturates are classified as ultra-short, short, intermediate, and long-acting. The Ultra-short barbiturates such as thiopental (Pentothal) produce unconsciousness within about a minute of intravenous (IV) injection. These drugs may be used to induce general anesthesia. Volatile anesthetics are then used to maintain general anesthesia until the end of the operation. Because thiopental and other ultrashort-acting barbiturates are typically used in hospital settings, they are not very likely to be abused, noted the DEA.[12] Barbiturate abusers prefer the short-acting and intermediate-acting barbiturates. After oral administration, the onset of action is from 15 to 40 minutes, and the effects last up to six hours. These drugs are primarily used for insomnia and preoperative sedation. Veterinarians use pentobarbital for anesthesia and euthanasia. Longacting barbiturates include phenobarbital (Luminal) and mephobarbital (Mebaral). Effects of these drugs are realized in about one hour and last for about 12 hours, and are used primarily for daytime sedation and the treatment of seizure disorders. Barbiturates contain a "balance" of hydrophilic (2,4,6-pyrimidinetrione ring structure) and lipophilic (5,5'-substituents) functionality. The overall hydrophilic (polar) or lipophilic (non-polar) character of the barbiturates is a function of: the hydrophilicity of the pyrimidinetrione ring which is a function of the number of N-substituents and the pKa of the acidic proton(s), and the overall size and structure of the two substituents at the 5-position. (See Fig.-1).[14-19]



Common Barbiturates structure

2.1 Mechanism of barbiturates action

The principal mechanism of action of barbiturates is believed to be their affinity for the GABA_A receptor (acts on GABA (Gamma-aminobutyric acid; H₂N(CH₂)₃COOH):benzodiazepine (BDZ) receptor Cl⁻ channel complex). The GABA receptors are a class of receptors that respond to gamma-aminobutyric the neurotransmitter acid (GABA), the chief neurotransmitter in the vertebrate central nervous system.[14,15] There are two classes of GABA receptors: GABA_A and GABA_B. GABA_A receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABA_B receptors are G protein-coupled receptors (also known as metabotropic receptors). Barbiturates bind to the GABAA receptor at the alpha subunit, which are binding sites distinct from GABA itself and also distinct from the benzodiazepine binding site.[20,21] Like benzodiazepines, barbiturates have similar effect of GABA at this receptor. In addition to this GABA-ergic effect, barbiturates also block the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor, a subtype of glutamate receptor.[20,21] The AMPA receptor (AMPAR, or quisqualate receptor) is a non ionotropic trans-membrane receptor types for glutamate that mediates fast synaptic transmission in the central nervous system (CNS). Its name is derived from its ability to be activated by the artificial glutamate analog AMPA.[21] Barbiturates produce their pharmacological effects by increasing the duration of chloride ion channel opening at the GABA_A receptor, increases the efficacy of GABA, whereas benzodiazepines increase the frequency of the chloride ion channel opening at the GABAA receptor to increase the potency of GABA. The direct gating or opening of the chloride ion channel is the reason for the increased toxicity of barbiturates compared to benzodiazepines in overdose. [20-23]

Barbiturates are relatively non-selective compounds that bind to an entire super-family of ligand-gated ion channels, of which the GABA_A receptor channel is only one of several representatives. While GABA_A receptor currents are increased by barbiturates (and other general anaesthetic compounds), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds.[12,24] The findings implicate (non-GABA-ergic) ligand-gated ion channels in mediating some of the (side) effects of barbiturates.[12,25]

In 1988, the synthesis and binding study of an artificial receptor binding barbiturates by 6 complementary hydrogen bonds was published by Chang and Hamilton.[26] According to this study, different kinds of receptors were designed, as well as different barbiturates and cyanurates, not for their efficiencies as drugs but for applications in supramolecular chemistry, in the conception of materials and molecular devices.[12,26] The actions of the barbiturates are described in more detail in the Pharmacology Notes. General properties of these compounds relatively concern to low "lipophilicity" and low plasma protein binding.[14-20]

Fig. 1. The Barbiturates **1-17** structures.

3. Octanol-water partition coefficient and biodegradation of barbiturates

The octanol-water partition coefficient (K_{ow}) is a measure of the equilibrium concentration of a compound between octanol and water that indicates the potential for partitioning in to soil organic matter (i.e., a high K_{ow} indicates a compound which will preferentially partition into soil organic matter rather than water). This coefficient is inversely related to the solubility of

a compound in water. The $logK_{ow}$ is used in models to estimate plant and soil invertebrate bioaccumulation factors. The $logK_{ow}$ is commonly used in QSAR studies and drug design, since this property is related to drug absorption, bioavailability, metabolism, and toxicity. This parameter is also used in many environmental studies to help determine the environmental fate of chemicals.[27,28] It has quite a lot of use in medicine and medicinal chemistry. Biodegradation (TB_d in mol/h)) is another useful and important factors in chemical and biochemical studies.[28]

It needs to use the effective and useful mathematical methods for making good concern between several data of chemical properties, medicinal chemistry and biological activity of chemicals.

Graph theory is an attractive field for the exploration of proof techniques in *Discrete Mathematics* and its results have applications in many areas of sciences. A graph is a topological concept rather than a geometrical concept of fixed geometry, and hence Euclidean metric lengths, angles and three-dimensional spatial configurations have no meaning.

Chemists employ various types of names and formulas when they wish to communicate information about chemicals and their structures. For the most part names and formulas have no direct, immediate or explicit mathematical meaning. Graph theory provides many different methods of characterizing chemical structures numerically.

It has been found to be a useful tool in *QSAR* (Quantitative Structure Activity Relationship) and *QSPR* (Quantitative Structure Property Relationship).[29-34] Numerous studies have been made relating to the above mentioned fields by using what are called topological indices (TI).[34,35]

In this study, will be considered the relationship of $Randi\acute{c}$ index, for molecular description of structure-property relationship studies for the logarithm of calculated Octanol-Water partitioning coefficients and total biodegradation ($logK_{ow}$ and TB_d (mol/h), respectively) in Barbiturate compounds (1-17).

4. Mathematical operations

The branching index that was introduced by $Randi\acute{c}$ is defined as the sum of certain bond contributions calculated from the degree of the bonds suppressed molecular graphs. These bond contributions, named C_{ij} are calculated as:

$$C_{ij} = (\delta_i \ \delta_j)^{-0.5} \tag{1}$$

Where δ_i is the degree of the vertex representing atom "i", i.e., the number of bonds incident to this atom. Accordingly, the *Randić* index is defined as: [29,35-38]

$$\chi = \Sigma C_{ij} = \Sigma (\delta_i \ \delta_i) - 0.5 \tag{2}$$

Where the summation is carried out over all the bonds of 1-17.

The inverse squared–root of the vertex degree is identified here as a measure of the relative accessible perimeter of an atom from the outside. These perimeters, which have length units, are proposed to be measured in a new unit called the *Randić* index (χ). On this basis, the

bond contributions to the *Randić* index are relative areas of bond accessibility from the environment.

All graphing operations were performed using the *Microsoft Office Excel*-2003 program. The data of Octanol-Water partitioning coefficients and total biodegradation ($logK_{ow}$ and TB_d , respectively) were calculated by EPI-suit v3.12 package [39].

5. Results and discussion

It was accepted that the organic compounds toxicity properties can be introduced by utilizing the $log K_{ow}$.[40] The quantitative structural activities and properties relationship results hold true for quite a lot of organic compounds, the most commonly used for test organism, follows this standard pattern. [41] Biodegradation is usually quantified by incubating a chemical compound in presence of a degrader, and measuring some factors like oxygen or production of CO₂. The biodegradation QSAR studies demonstrate that microbial biosensors are a viable alternative means of reporting on potential biotransformation. However, a few chemicals are tested and large data sets for different chemicals need for QSAR modeling [42]. This study shows the structural relationship between $Randi\acute{c}$ index (χ), $log K_{ow}$ and total biodegradation (TB_d) for barbiturates (1-17). The values of the relative structural coefficients of the barbiturates structures (1-17), Randić index (χ) to logarithm of Octanol-Water partitioning coefficients ($log K_{ow}$) and calculated total biodegradation (TB_d) in mol/h, data were shown in Table-1. The χ values of 1-17 increase with the increasing the number of branches in the appropriate structures. The *Randić* index (χ) for barbituric acid (1) in respect with the branches of the structure is equal to 2.1216. See equations 1 and 2 and the appropriate data extended in Table-1 for other members of these group.

$$\chi = 6[(2\times4)^{-0.5}] = 2.1216$$




Fig. 2. The linear relationship between the values of $log(K_{ow})$ versus the Randic Indices (χ) for Barbiturates (1-17).

$$R_{1}$$
 R_{2}
 R_{4}
 R_{4}
 R_{3}
 R_{4}
 R_{4}
 R_{3}

No.	Rı	R ₂	R_3	R ₄	Randic Indices (χ)	Log K _{ow}	TB _d ×10- 5 (mol/h)
1	H		Н	H	2.1216	-1.2488	7.2
2	Н	Н	CH_3	CH_3	3.0166	-0.8264	5.9
3	CH_3	CH_3	Н	Н	2.4144	-0.3777	5.9
4	Н	Н	CH_3	C_2H_5	3.4751	-0.1289	5.4
5	CH_3	Н	C_2H_5	Н	4.0358	0.6045	5.0
6	$(CH_2)_2CH(CH_3)_2$	C_2H_5	Н	Н	5.3911	2.0043	4.2
7	CH(CH ₃)CH ₂ CH ₃	C_2H_5	CH_3	Н	4.8266	1.7244	4.1
8	$CH(CH_3)(CH_2)_2CH_3$	C_2H_5	Н	Н	5.4564	2.0043	4.3
9	CH(CH ₃)CH ₂ CH ₃	C_2H_5	Н	Н	4.9564	1.5132	4.4
10	$CH(CH_3)(CH_2)_3CH_3$	Н	Н	Н	4.7188	1.5508	4.4
11	$CH(CH_3)(CH_2)_3CH_3$	C_2H_5	CH_3	CH_3	5.9978	2.9178	4.4
12	CH ₂ -CH=CH2	$CH(CH_3)(CH_2)_2CH_3$	Н	Н	5.3152	2.3590	4.0
13	CH ₂ -CH=CH2	$CH(CH_3)_2$	Н	Н	4.5277	1.3768	4.4
14		CH ₃	CH ₃	Н	4.3593	1.8548	3.8
15	C_6H_5 -	C_2H_5	Н	Н	4.8025	1.3301	4.0
15	C ₆ H ₅ -	C_2H_5	CH_3	Н	5.0059	1.5413	3.8
17	C ₆ H ₅ -	C_2H_5	CH_3	CH_3	4.8761	1.7525	3.6

Table 1. The values of the relative structural coefficients of Barbiturates structures (1-17).

In Fig.-2 to Fig.-4 were shown two dimensional diagrams of the relationship between the values of $Randi\acute{c}$ index, $log K_{ow}$ and TB_d .

The figure 2 shows a good linear relationship between the values of $log(K_{ow})$ versus the Randic Indices (χ) for barbiturates (1-17). The Eq.-3 is relevant to Fig.-2, and as could see by this equation can extend the linear behavior of the calculated $logK_{ow}$ and χ for these compounds. The R-squared value (R^2) for this graph is equal to 0.9248.

$$log(K_{ow}) = 1.0309(\chi) - 3.3924 \tag{3}$$

By this way, equation 3 afford a good approximation for calculation of logarithm value of Octanol-Water partitioning coefficient ($log K_{ow}$) by the use of $Randi\acute{c}$ index (χ) and directly for the barbiturates. The large values results for solving the first order Eq.-3 are acceptable. For achieving to $log K_{ow}$ can use directly from Eq.-3, in accordance with the structural " χ " values for these compounds.

The Fig.-3 shows a curve for relationship between the values of calculated total biodegradation (TB_d) versus the Randic Indices (χ) for **1-17**. The Eq.-4 is relevant to Fig.-4,

and can see the non linear behavior of the calculated total biodegradation (TB_d) and χ for barbiturates (1-17). The equation has three-order structure. The R-squared value (R^2) for this graph shows 0.8916.

$$TB_d = 0.0825(\chi)^3 - 0.7268(\chi)^2 + 0.901(\chi) + 7.4083$$
 (4)




Fig. 3. A curve between values of *Randić* indices (χ) and calculated total biodegradation (TB_d) for **(1-17)**.

By the use of Randic Indices (χ) for **1-17** in the Eq.-4 can achieve to an approximation for total biodegradation (TB_d). All values of TB_d should multiply to 10^{-5} for achieving to calculated total biodegradation in mol/h for the compounds.

A plot of the $log(K_{ow})$ versus the calculated total biodegradation (TB_d) for Barbiturates (1-17) was demonstrated in Fig.-4. The equation of this relationship has three-order structure and introduced by Eq.-5. The R-squared value (R^2) for this graph is equal to 0.9243.

$$TB_d = 0.0286(\log K_{ow})^3 + 0.1884(\log K_{ow})^2 - 1.1251(\log K_{ow}) + 5.314$$
 (5)

It seems that two methods were achieved for TB_d calculation of barbiturates (1-17). One of these two models, is calculation of Randic Indices (χ) for these important compounds by the use of Eq.-4.

The second method is the measurement of $\log K_{ow}$ by the use of (χ) in equations 3, then utilize the result in Eq.-5. In respect with the R-squared value (R²) for these graphs it is obvious that the second model much better for this relationship. Determination of $\log K_{ow}$ and TB_d for the barbiturates as an important class of medicinal compounds have highly importance and the models that were demonstrated here show simple methods for this matter.




Fig. 4. A plot of the $log(K_{ow})$ versus the calculated total biodegradation (TB_d) for Barbiturates (1-17).

6. Conclusion

Barbiturates are primarily used for insomnia and preoperative sedation. These drugs contain a "balance" of hydrophilic and lipophilic functionality. General properties of these compounds relatively concern to low "lipophilicity" and low plasma protein binding. Graph theory has been found to be an effective tool in QSAR and QSPR. Topological inices (TIs) contain valuable structural information as evidenced by the success of their widespread applications in QSAR. One of the useful descriptors for examination of structure-property relationship is $Randi\acute{c}$ index. The lipophilicity and toxicity properties of organic compounds can be predicted on the basis of the $logK_{ow}$. The biodegradation QSAR studies demonstrate that microbial biosensors are a viable alternative means of reporting on potential biotransformation. In this study, was considered the relationship of $Randi\acute{c}$ indeices, logarithm of calculated Octanol-Water partitioning coefficients and total biodegradation ($logK_{ow}$ and TB_d (mol/h), respectively) with each other for barbiturates. Randic Indices (χ) show a good differences between the values of $logK_{ow}$ and TB_d as two important factors in chemical and biochemical studies in these compounds.

7. Acknowledgment

The authors gratefully acknowledge Dr. Arezou Taherpour for the useful suggestions.

8. References

- [1] a) http://en.wikipedia.org/wiki/Insomnia. b) Roth, Thomas (15 August 2007). "Insomnia: Definition, Prevalence, Etilogy, and Consequences" (Full text). *J Clin Sleep Med* (American Academy of Sleep Medicine) 3(5 Suppl) (5 Suppl): S7–S10.
- [2] c) Morin, C. M. (2000). "The Nature of Insomnia and the Need to Refine Our Diagnostic Criteria" (Editorial). *Psychosomatic Medicine* **62** (4): 62:483–485. http://www.psychosomaticmedicine.org/cgi/content/full/62/4/483. Retrieved 2010-01-07.
- [3] d) Hirshkowitz, M. (2004). "Chapter 10, Neuropsychiatric Aspects of Sleep and Sleep Disorders (pp 315-340)". In Stuart C. Yudofsky and Robert E. Hales, editors (Google Books preview includes entire chapter 10). Essentials of neuropsychiatry and clinical neurosciences (4 Ed.). Arlington, Virginia, USA: American Psychiatric Publishing.
- [4] e)http://www.who.int/selection_medicines/committees/expert/17/application/Section2 4_GAD.pdf. Retrieved 2009-01-25.
- [5] f) http://www.webmd.com/sleep-disorders/guide/insomnia-symptoms-and-causes.
- [6]Insomnia. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/dci/Diseases/inso/inso_all.html. Oct. 7, 2010.
- [7] Approach to the patient with a sleep or wakefulness disorder. The Merck Manuals: The Merck Manual for Healthcare Professionals. http://www.merck.com/mmpe/print/sec16/ch215/ch215b.html. Oct. 7, 2010.
- [8] Ancoli-Israel S. Sleep and its disorders in aging populations. Sleep Medicine. 2009;10:S7.
- [9] Doghramji K. (2010) The evaluation and management of insomnia. Clinics in Chest Medicine. 31:327.
- [10] Wortelboer U., Cohrs S., Rodenbeck A., Rüther E. (2002) "Tolerability of hypnosedatives in older patients". *Drugs Aging*, 19 (7): 529–39.
- [11] Flamer H. E. (June 1995). "Sleep problems". Med. J. Aust., 162 (11): 603-7.
- [12] http://www.dignitas.ch/index.php?option=com_content&view=article&id=22&Itemid =62& lang=de. Retrieved 2011-06-14.
- [13] "Barbiturates: How Is It Taken?". *Azdrugs. Org.* 2005–2007. http://azdrugs.org/barbiturates/how-taken. Retrieved 2007-10-31.
- [14] Lopez-Munoz F., Ucha-Udabe R., Almao C. (2005) Neuropsy.Dise.& Treat., 1(4), 329-343.
- [15] Wallner M., Hanchar J. H., Olsen W. R. (2006) Pharma. & Therap., 112(2), 513-528.
- [16] Lanfont O., Talab A., Menager S., Vave C., Miocque M. (1990) Eur. J. Medic. Chem., 25(2), 179-186.
- [17] Shimazono N. (1961) Bitamin, 24(1), 1-9.
- [18] Wasternack C. (1980) *Pharm. & Thera.*, 8(3), 629-651.
- [19] For some useful information about Barbiturates see: http://www.duc.auburn.edu/~deruija/GABA_Barbiturates2002.pdf#search='Barbiturates%20structures' and http://www.streetdrugs.org/barbiturates.htm.

- [20] Brunton, Laure L.; Lazo, John S.; Parker, Keith L.; Goodman, Louis Sanford; Gilman, Alfred Goodman (2005). *Goodman & Gilman's Pharmacological Basis of Therapeutics*. McGraw-Hill.
- [21] a)http://en.wikipedia.org/wiki/GABAA_receptor. b)http://en.wikipedia.org/wiki/A MPA_receptor.
- [22] Harrison N.; Mendelson W. B. and de Wit H. (2000). "Barbiturates".

 Neuropsychopharmacology.


 http://www.acnp.org/g4/GN401000173/CH169.html.

 Retrieved 15 July 2008.
- [23] Society for Neurochemistry, American; George J. Siegel M.D., Bernard W. Agranoff M.D., Stephen K. Fisher Ph.D., R. Wayne Albers Ph.D., Michael D. Uhler Ph.D. (1999). "Part 2 Chapter 16". *Basic Neurochemistry Molecular, Cellular and Medical Aspects* (Sixth ed.). Lippincott Williams and Wilkins.
- [24] http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=bnchm.section.1181.Retrieved July 2008.
- [25] Weber, M; Motin, L; Gaul, S; Beker, F; Fink, RH; Adams, DJ (January 2005). "Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons." *British Journal of Pharmacology* 144 (1): 98–107.
- [26] Chang, Suk K..; Hamilton, Andrew D. (1988). "Molecular recognition of biologically interesting substrates: Synthesis of an artificial receptor for barbiturates employing six hydrogen bonds". *Journal of the American Chemical Society* 110 (4): 1318–1319.
- [27] Hansch C., Leo A. and Hoekman D. (1995) *Exploring QSAR: Hydrophobic, Electronic, Steric Constants*, ACS, Washington, DC, USA.
- [28] Bundy J. G., Morriss A. W. J., Durham D. G., Campbell C. D. and Paton G. I. (2001) *Chemosphere*, 42, 885-892. (and the literature cited there in).
- [29] Hansen P. J. and Jurs P. (1988) *J. Chem. Edu.*, 65, 574-580. (and the literature cited therein).
- [30] Hosoya H. (1971) Bull. Chem. Soc. Jpn., 44, 2332-2339.
- [31] Randić M (1998) Acta Chim. Slov., 45, 239-252.
- [32] Rücker G. and Rücker C. (1999) J. Chem. Inf. Cmput. Sci., 39, 788-802.
- [33] Wiener H. (1947) J. Am. Chem. Soc., 17-20.
- [34] Du Y. P., Liang Y. Z., Li B. Y. and Xu C. J. (2002) J. Chem. Inf. Cmput. Sci., 42, 1128-1138.
- [35] Randić M. (1975) J. Am. Chem. Soc., 97, 6609-6615.
- [36] Kier L. B., Hall L.H. (2000) J. Chem. Inf. Comput.. Sci., 40, 729-795.
- [37] Estrada E. (2002) Internet Electron. J. Mol. Des., 1, 360-366.
- [38] Kier L. B. and Hall L. H. (1976) Molecular Connectivity in Chemistry and Drug Research, Academic Press, New York.
- [39] For study about the EPI-suit v4.00, See US *Environmental Protection Agency* site: http://www.epa.gov/epahome/docs
- [40] Cronin M. T. D. and Dearden J. C. (1995) Quant. Struct. -Act. Relat., 14, 1-7.

- [41] Hermens J. L. M. and Verhaar H. J. M. (1995) *QSARs in Environmental Toxicology Chemistry*. ACS Symposium Series 606, 130-140.
- [42] Degner P., Nendza M. and Klein W. (1991) Sci. Total Environ., 109, 253-259.







Can't Sleep? Issues of Being an Insomniac

Edited by Dr. Saddichha Sahoo

ISBN 978-953-51-0261-8
Hard cover, 110 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012

The word insomnia originates from the Latin "in" (no) and "somnus" (sleep). It is a disorder characterized by an inability to sleep or a complete lack of sleep. Various studies have noted insomnia to be quite a common condition, with symptoms present in about 33-50% of the adult population. This book provides a comprehensive state of the art review on the diagnosis and management of the current knowledge of insomnia and is divided into several sections, each detailing different issues related to this problem, including epidemiology, diagnosis, management, quality of life and psychopharmacology. In order to present a balanced medical view, this book was edited by a clinical psychiatrist.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Avat (Arman) Taherpour, Zhiva Taherpour and Omid Taherpour (2012). Structural Relationship Study of Octanol-Water Partitioning Coefficients and Total Biodegradation of Barbiturate Medicines by Randić Descriptor, Can't Sleep? Issues of Being an Insomniac, Dr. Saddichha Sahoo (Ed.), ISBN: 978-953-51-0261-8, InTech, Available from: http://www.intechopen.com/books/can-t-sleep-issues-of-being-an-insomniac/structural-relationship-study-of-octanol-water-partitioning-coefficients-4and-total-biodegradation-o



InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447

Fax: +385 (51) 686 166 www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元

Phone: +86-21-62489820 Fax: +86-21-62489821 © 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the <u>Creative Commons Attribution 3.0</u> <u>License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



